Trade Elicit Therapeutics Inc. - ELTX CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0892 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 9.1954 |
Open | 9.1754 |
1-Year Change | 1140.42% |
Day's Range | 8.8154 - 9.2754 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 24, 2024 | 9.1854 | 0.0100 | 0.11% | 9.1754 | 9.2954 | 8.8154 |
Apr 23, 2024 | 9.1954 | -0.1100 | -1.18% | 9.3054 | 9.3354 | 8.6154 |
Apr 22, 2024 | 9.4754 | 1.3000 | 15.90% | 8.1754 | 9.7754 | 7.9554 |
Apr 19, 2024 | 8.3554 | 0.3800 | 4.76% | 7.9754 | 8.7954 | 7.9754 |
Apr 18, 2024 | 8.1654 | -0.8300 | -9.23% | 8.9954 | 8.9954 | 7.8554 |
Apr 17, 2024 | 9.1454 | -0.1700 | -1.82% | 9.3154 | 9.6754 | 8.4754 |
Apr 16, 2024 | 9.4454 | 0.2400 | 2.61% | 9.2054 | 9.5454 | 9.2054 |
Apr 15, 2024 | 8.9554 | -0.9200 | -9.32% | 9.8754 | 10.1754 | 8.5454 |
Apr 12, 2024 | 9.8254 | 0.7500 | 8.26% | 9.0754 | 9.8254 | 9.0754 |
Apr 11, 2024 | 9.6454 | 0.9200 | 10.54% | 8.7254 | 9.6454 | 8.4754 |
Apr 10, 2024 | 8.4754 | -0.3000 | -3.42% | 8.7754 | 8.8754 | 8.3654 |
Apr 9, 2024 | 8.6354 | -0.0900 | -1.03% | 8.7254 | 9.0354 | 8.3254 |
Apr 8, 2024 | 8.6354 | -0.3000 | -3.36% | 8.9354 | 9.6554 | 8.2954 |
Apr 5, 2024 | 8.5654 | 1.2300 | 16.77% | 7.3354 | 8.9154 | 7.3254 |
Apr 4, 2024 | 7.3454 | 0.0500 | 0.69% | 7.2954 | 7.5254 | 7.1754 |
Apr 3, 2024 | 7.2754 | -0.2000 | -2.68% | 7.4754 | 7.4854 | 6.8754 |
Apr 2, 2024 | 7.0754 | 0.0300 | 0.43% | 7.0454 | 7.4054 | 6.6754 |
Apr 1, 2024 | 7.0854 | -0.0100 | -0.14% | 7.0954 | 7.1454 | 6.5954 |
Mar 28, 2024 | 7.5754 | 0.1700 | 2.30% | 7.4054 | 7.7654 | 7.2254 |
Mar 27, 2024 | 7.3154 | 0.6000 | 8.93% | 6.7154 | 7.3654 | 6.7154 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Angion Biomedica Corp. Company profile
About Angion Biomedica Corp
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com